Presented in the context of an MGMT-null GBM model, our findings of reduced EGFR expression and downstream AKT and STAT3 activation in quiescent and TMZ-resistant GSCs complement the findings of Struve et al and point to an important consideration across all GBM research. The gene discussed is MGMT; the disease is glioblastoma.